LITS

#4418
Lite Strategy, Inc. - Common Stock
0.9 8 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.98
0.98
Intervallo Annuale
0.69
3.23
Variazione giornaliera
-2.00%
Variazione Mensile
+1.03%
Variazione di 6 mesi
-9.26%
Variazione Annuale
-67.11%
Chiusura Precedente
1.0 0
Open
0.9 8
Minimo
0.9 8
Massimo
0.9 8
Volume
2
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi Documents

2026

Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Lite Strategy, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Lite Strategy, Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K

2025

Quarterly report, Q2 FY2025
Lite Strategy, Inc. quarterly report, Q2 FY2025
10-Q
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K

Lite Strategy, Inc. current report, 17 July 2023

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on July 17, 2023. The filing addresses Item 8.01 (Other Events) regarding a proposed merger with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI). The Company issued a press release encouraging shareholders to vote FOR the transaction at a special meeting scheduled for July 23, 2023.

Key Financial Metrics

This filing is a current report regarding a corporate event and does not contain specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity data for the reporting period. Investors are directed to the Joint Proxy Statement/Prospectus (Form S-4) and recent 10-K/10-Q filings for detailed financial information.

Material Changes

  • Merger Proposal: A proposed transaction with Infinity Pharmaceuticals is pending, requiring shareholder approval.
  • Regulatory Status: The Joint Proxy Statement/Prospectus was declared effective by the SEC on June 6, 2023.
  • Shareholder Action: A special meeting is set for July 23, 2023, to vote on the merger.

Guidance, Outlook, and Risks

Management Commentary: Management urges stockholders to read the Joint Proxy Statement/Prospectus in its entirety for important information regarding the proposed merger. The filing includes a press release (Exhibit 99.1) soliciting votes in favor of the transaction.

Risks and Contingencies: The filing contains extensive forward-looking statements and risk factors, including:

  • Risk that the merger may not be completed in a timely manner or at all.
  • Uncertainties regarding stockholder and regulatory approvals.
  • Potential disruption to business operations, retention of key personnel, and relationships with suppliers/customers.
  • Unexpected costs, liabilities, or delays associated with the merger.
  • Risks related to the development, safety, efficacy, and regulatory approval of product candidates.
  • Impact of the COVID-19 pandemic on clinical development and financing.

Investor Verification Checklist

  • Verify the details of the merger agreement and exchange ratio in the Joint Proxy Statement/Prospectus (Form S-4) filed on June 6, 2023.
  • Confirm the outcome of the special shareholder meeting scheduled for July 23, 2023.
  • Review the "Risk Factors" section in the Form S-4 and the most recent 10-K filings for both MEI Pharma and Infinity Pharmaceuticals.
  • Monitor for any updates regarding regulatory approvals required to consummate the transaction.